For instance, large-scale trials of modern GLP-1RAs began over a decade ago and have enrolled over 70,000 patients collectively, with some individual trials following patients for 5-7 years
Furanodienone induces G0/G1 arrest and causes apoptosis via the ROS/MAPKs-mediated caspase-dependent pathway in human colorectal cancer cells: a study in vitro and in vivo
Haematologica 102:14941501
Because survodutide is earlier in its trial lifecycle, its longer-term safety data is less complete than tirzepatides, which has accumulated monitoring data across a larger number of study participants and a longer observation window
[11] [12] Patients should be aware of symptoms such as right upper abdominal pain, fever, or jaundice
It is hypothesized that the slowing of gastric emptying contributes to some of the more common adverse events that occur with tirzepatide and selective GLP-1RAs (e.g., nausea, diarrhea, and vomiting), as the incidence of these events most commonly coincides with the timing of the early gastric slowing